Cerus reports preliminary 2022 product revenue of $162M, up 24% YoY, and guides 2023 revenue $165-170M

CERUS CORP

2022-FY EPS reported -$0.24 revenue$188,315,000

Preliminary Q4 2022 product revenue $44.0M, up 10% from Q4 2021.
Full-year 2022 product revenue $162.0M, at top end of guidance, up 24% year-over-year.
2023 product revenue guidance range of $165-170M, citing macroeconomic uncertainty and FX headwinds.
CEO Obi Greenman notes consistent commercial execution and growing demand for INTERCEPT Blood System in U.S.
Company expects 2023 to be a bridge year with uncertainty most acute in Q1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CERUS CORP reported the fourth quarter and fiscal year ended December 31, 2022 results: revenue $44.0 million. Guidance initiated.

Period: the fourth quarter and fiscal year ended December 31, 2022
Revenue: $44.0 million
Guidance: initiated
Result: preliminary results

Exact text from the filing

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update Preliminary Fourth Quarter and Full-Year 2022 Product Revenues of $44.0 million and $162.0 million reflecting year-over-year growth of 10% and 24%, respectively

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

CERUS CORP filing history →

Source: SEC EDGAR

accession 0001193125-23-004227

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.